• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Research and Markets: Guillain Barre Syndrome (GBS) Therapeutics Pipeline Assessment and Market Forecasts to 2017 (Predicting increasing cases)

Emily

Emily

Editor, Senior Moderator
Some highlights from the article:

  • Predicted increase in the prevalence of the disease through 2017.
  • There is a lack of adequate treatment options, difficulties in diagnosis and a low efficacy and safety profile of the available treatment options.
  • The cost of therapy for the current treatment options is high.

http://www.businesswire.com/news/home/20110722005439/en/Research-Markets-Guillain-Barre-Syndrome-GBS-Therapeutics
July 22, 2011 04:25 PM Eastern Daylight Time
Research and Markets: Guillain Barre Syndrome (GBS) Therapeutics Pipeline Assessment and Market Forecasts to 2017 - The GBS Therapeutics Market has High Unmet Need

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/26d5d7/guillain_barre_syn) has announced the addition of GlobalData's new report "Guillain Barre Syndrome (GBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering. ....
Click to expand...
 
You must log in or register to reply here.
Back
Top Bottom